Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A031102||Alliance||A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel; Ifosfamide; and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1802||SWOG||Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|EAZ171||ECOG-ACRIN||Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women||Cancer Prevention and Control CIRB||Available to Open|
|ALTE11C2||COG||Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy: A Limited Institution Non-Therapeutic Study||Pediatric CIRB||Available to Open|
|ADVL1521||COG||A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia||Pediatric CIRB||Available to Open|
|A021602||Alliance||Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-LU004||NRG||Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined With MEDI4736 (durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)||Adult CIRB - Early Phase Emphasis||Available to Open|
|10010||ETCTN||A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination with Bevacizumab in Patients with Recurrent; Persistent or Metastatic Cervical Cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|AALL15P1||COG||A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND#TBD; NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A Gene Rearrangement||Pediatric CIRB||Available to Open|
|E5508||ECOG||Randomized Phase III Study of Maintenance Therapy with Bevacizumab; Pemetrexed; or a Combination of Bevacizumab and Pemetrexed Following Carboplatin; Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC||Adult CIRB - Late Phase Emphasis||Available to Open|